These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25022374)

  • 1. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
    Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
    Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
    BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
    van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
    Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
    Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
    Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
    Hussain M; Rathkopf D; Liu G; Armstrong A; Kelly WK; Ferrari A; Hainsworth J; Joshi A; Hozak RR; Yang L; Schwartz JD; Higano CS
    Eur J Cancer; 2015 Sep; 51(13):1714-24. PubMed ID: 26082390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?
    Kongsted P; Svane IM; Lindberg H; Daugaard G; Sengeløv L
    Urol Oncol; 2015 Nov; 33(11):494.e15-20. PubMed ID: 26254696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
    Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
    Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices.
    Sonpavde G; Bhor M; Hennessy D; Bhowmik D; Shen L; Nicacio L; Rembert D; Yap M; Schnadig I
    Clin Genitourin Cancer; 2015 Aug; 13(4):309-318. PubMed ID: 25743206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
    Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
    BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
    Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
    Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.
    Bouman-Wammes EW; van den Berg HP; de Munck L; Beeker A; Smorenburg CH; Vervenne WL; Coenen JLLM; Verheul HMW; Gerritsen WR; Van den Eertwegh AJM
    Eur J Cancer; 2018 Feb; 90():1-9. PubMed ID: 29268139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
    Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
    Puente J; González-Del-Alba A; Sala-Gonzalez N; Méndez-Vidal MJ; Pinto A; Rodríguez Á; Cuevas Sanz JM; Muñoz Del Toro JR; Useros Rodríguez E; García García-Porrero Á; Vázquez S
    BMC Cancer; 2019 Aug; 19(1):766. PubMed ID: 31382926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.